Thera-SAbDab

NIRSEVIMAB

>   Structural Summary
TherapeuticNirsevimab
TargetRSV
Heavy ChainQVQLVQSGAEVKKPGSSVMVSCQASGGLLEDYIINWVRQAPGQGPEWMGGIIPVLGTVHYGPKFQGRVTITADESTDTAYMELSSLRSEDTAMYYCATETALVVSETYLPHYFDNWGQGTLVTVSS
Light ChainDIQMTQSPSSLSAAVGDRVTITCQASQDIVNYLNWYQQKPGKAPKLLIYVASNLETGVPSRFSGSGSGTDFSLTISSLQPEDVATYYCQQYDNLPLTFGGGTKVEIK
100% seqID Fv Structure5udc [Fvs: BC, EG, HL], 5udd [Fvs: JP, KQ, LR, MS, NT, OU]
99% seqID Fv StructureNone
95-98% seqID Fv Structure4jha [Fvs: HL], 4jhw [Fvs: HL], 6s3d [Fvs: AB, CD, EF, HL]
>   Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Nirsevimab.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

Sequence identity: 96.14%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 100D 100E 100F 100G 100H 100I 101 102 103 104 105 106 107 108 109 110 111 112 113
nirsevimab Q V Q L V Q S G A E V K K P G S S V M V S C Q A S G G L L E D Y I I N W V R Q A P G Q G P E W M G G I I P V L G T V H Y G P K F Q G R V T I T A D E S T D T A Y M E L S S L R S E D T A M Y Y C A T E T A L V V S E T Y L P H Y F D N W G Q G T L V T V S S
4jha Q V Q L V Q S G A E V K K P G S S V M V S C Q A S G G P L R N Y I I N W L R Q A P G Q G P E W M G G I I P V L G T V H Y A P K F Q G R V T I T A D E S T D T A Y I H L I S L R S E D T A M Y Y C A T E T A L V V S T T Y L P H Y F D N W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
nirsevimab D I Q M T Q S P S S L S A A V G D R V T I T C Q A S Q D I V N Y L N W Y Q Q K P G K A P K L L I Y V A S N L E T G V P S R F S G S G S G T D F S L T I S S L Q P E D V A T Y Y C Q Q Y D N L P L T F G G G T K V E I K
4jha D I Q M T Q S P S S L S A A V G D R V T I T C Q A S Q D I V N Y L N W Y Q Q K P G K A P K L L I Y V A S N L E T G V P S R F S G S G S G T D F S L T I S S L Q P E D V A T Y Y C Q Q Y D N L P L T F G G G T K V E I K
Sequence identity: 96.14%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 100D 100E 100F 100G 100H 100I 101 102 103 104 105 106 107 108 109 110 111 112 113
nirsevimab Q V Q L V Q S G A E V K K P G S S V M V S C Q A S G G L L E D Y I I N W V R Q A P G Q G P E W M G G I I P V L G T V H Y G P K F Q G R V T I T A D E S T D T A Y M E L S S L R S E D T A M Y Y C A T E T A L V V S E T Y L P H Y F D N W G Q G T L V T V S S
4jhw Q V Q L V Q S G A E V K K P G S S V M V S C Q A S G G P L R N Y I I N W L R Q A P G Q G P E W M G G I I P V L G T V H Y A P K F Q G R V T I T A D E S T D T A Y I H L I S L R S E D T A M Y Y C A T E T A L V V S T T Y L P H Y F D N W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
nirsevimab D I Q M T Q S P S S L S A A V G D R V T I T C Q A S Q D I V N Y L N W Y Q Q K P G K A P K L L I Y V A S N L E T G V P S R F S G S G S G T D F S L T I S S L Q P E D V A T Y Y C Q Q Y D N L P L T F G G G T K V E I K
4jhw D I Q M T Q S P S S L S A A V G D R V T I T C Q A S Q D I V N Y L N W Y Q Q K P G K A P K L L I Y V A S N L E T G V P S R F S G S G S G T D F S L T I S S L Q P E D V A T Y Y C Q Q Y D N L P L T F G G G T K V E I K
Sequence identity: 96.14%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 100D 100E 100F 100G 100H 100I 101 102 103 104 105 106 107 108 109 110 111 112 113
nirsevimab Q V Q L V Q S G A E V K K P G S S V M V S C Q A S G G L L E D Y I I N W V R Q A P G Q G P E W M G G I I P V L G T V H Y G P K F Q G R V T I T A D E S T D T A Y M E L S S L R S E D T A M Y Y C A T E T A L V V S E T Y L P H Y F D N W G Q G T L V T V S S
6s3d Q V Q L V Q S G A E V K K P G S S V M V S C Q A S G G P L R N Y I I N W L R Q A P G Q G P E W M G G I I P V L G T V H Y A P K F Q G R V T I T A D E S T D T A Y I H L I S L R S E D T A M Y Y C A T E T A L V V S T T Y L P H Y F D N W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
nirsevimab D I Q M T Q S P S S L S A A V G D R V T I T C Q A S Q D I V N Y L N W Y Q Q K P G K A P K L L I Y V A S N L E T G V P S R F S G S G S G T D F S L T I S S L Q P E D V A T Y Y C Q Q Y D N L P L T F G G G T K V E I K
6s3d D I Q M T Q S P S S L S A A V G D R V T I T C Q A S Q D I V N Y L N W Y Q Q K P G K A P K L L I Y V A S N L E T G V P S R F S G S G S G T D F S L T I S S L Q P E D V A T Y Y C Q Q Y D N L P L T F G G G T K V E I K
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Phase-III
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2018
INN Year Recommended2019
Companies InvolvedAIMM Therapeutics, MedImmune
Conditions Approvedna
Conditions ActiveRespiratory syncytial virus infections
Conditions Discontinuedna
Notes

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy